Chuan Ye
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Chuan Ye has a total of 62 co-authors. Here are the top co-authors by number of shared publications:
- Changtao Jiang
Department of Immunology, School of Basic Medical Sciences, Peking University, Beijing, China
4 shared publications Jun Lin
Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Center for Reproductive Medicine, Third Hospital, Peking University, Beijing, China
2 shared publications- Min Zhao
State Key Laboratory of Female Fertility Promotion, Center for Reproductive Medicine, Department of Obstetrics and Gynecology, Peking University Third Hospital, Beijing, China
2 shared publications - Pengyan Xia
Peking University
2 shared publications Qixing Nie
Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Center for Reproductive Medicine, Third Hospital, Peking University, Beijing, China
2 shared publications- Sen Yan
State Key Laboratory of Female Fertility Promotion, Center for Reproductive Medicine, Department of Obstetrics and Gynecology, Peking University Third Hospital, Beijing, China
2 shared publications
Latest Publications
- Open Access
Evidence-resolved benchmarks separate biological context recognition from direct-partner specificity in protein interaction models
Sequence-based models enable scalable protein–protein interaction (PPI) prediction, but whether high scores identify direct physical partners or broader biological compatibility remains unclear. Here we show that biological-context recognition and direct-partner specificity are separable prediction capabilities. We introduce ProtNegDB ( http://protnegdb.bjmu.edu.cn/ ), an evidence-resolved resource distinguishing experimentally supported non-binding from coordinate-verified noncontact within PDB biological assemblies. Using context-matched benchmarks, we find that five sequence-based predictors show limited ability to distinguish direct partners from noncontacting members of the same assembly, whereas PLM-Interact readily ranks both above unrelated proteins. Representation analyses reveal that adaptation to PPI prediction can strengthen biological-context encoding without yielding transferable direct-contact specificity. AlphaFold3 shows greater, though still incomplete, direct-partner resolution, suggesting that explicit multimer modeling can help refine partner specificity. In PLM-Interact, negatives defined by reconstituted direct-binding, cellular binary/proximity and co-complex assays occupy distinct score regimes. Across independent datasets and multiple models, experimental direct non-binding and assembly noncontact further show reproducible, model-dependent scoring patterns. High sequence-based PPI scores should not be interpreted as direct-interface probabilities. Mechanistically interpretable evaluation instead requires explicit consideration of interaction-evidence semantics and partner specificity.
Open AccessEvidence-resolved benchmarks separate biological context recognition from direct-partner specificity in protein interaction models
Sequence-based models enable scalable protein–protein interaction (PPI) prediction, but whether high scores identify direct physical partners or broader biological compatibility remains unclear. Here we show that biological-context recognition and direct-partner specificity are separable prediction capabilities. We introduce ProtNegDB ( http://protnegdb.bjmu.edu.cn/ ), an evidence-resolved resource distinguishing experimentally supported non-binding from coordinate-verified noncontact within PDB biological assemblies. Using context-matched benchmarks, we find that five sequence-based predictors show limited ability to distinguish direct partners from noncontacting members of the same assembly, whereas PLM-Interact readily ranks both above unrelated proteins. Representation analyses reveal that adaptation to PPI prediction can strengthen biological-context encoding without yielding transferable direct-contact specificity. AlphaFold3 shows greater, though still incomplete, direct-partner resolution, suggesting that explicit multimer modeling can help refine partner specificity. In PLM-Interact, negatives defined by reconstituted direct-binding, cellular binary/proximity and co-complex assays occupy distinct score regimes. Across independent datasets and multiple models, experimental direct non-binding and assembly noncontact further show reproducible, model-dependent scoring patterns. High sequence-based PPI scores should not be interpreted as direct-interface probabilities. Mechanistically interpretable evaluation instead requires explicit consideration of interaction-evidence semantics and partner specificity.
- Top Cited Papers
- 1 May 2025
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 388 (6746) , eado4188
Metabolic signaling of ceramides through the FPR2 receptor inhibits adipocyte thermogenesis
Ceramides play a central role in human health and disease, yet their role as systemic signaling molecules remain poorly understood. In this work, we identify formyl peptide receptor 2 (FPR2) as a membrane receptor that specifically binds long-chain ceramides (C14 to C20). In brown and beige adipocytes, C16:0 ceramide binding to FPR2 inhibits thermogenesis through G i cyclic adenosine monophosphate signaling pathways, an effect that is reversed in the absence of FPR2. We present three cryo–electron microscopy structures of FPR2 in complex with G i trimers bound to C16:0, C18:0, and C20:0 ceramides. The hydrophobic tails are deeply embedded in the orthosteric ligand pocket, which has a limited amount of plasticity. Modification of the ceramide binding motif in closely related receptors, such as FPR1 or FPR3, converts them from inactive to active ceramide receptors. Our findings provide a structural basis for adipocyte thermogenesis mediated by FPR2.
- 1 May 2025
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 388 (6746) , eado4188
Top Cited PapersMetabolic signaling of ceramides through the FPR2 receptor inhibits adipocyte thermogenesis
Ceramides play a central role in human health and disease, yet their role as systemic signaling molecules remain poorly understood. In this work, we identify formyl peptide receptor 2 (FPR2) as a membrane receptor that specifically binds long-chain ceramides (C14 to C20). In brown and beige adipocytes, C16:0 ceramide binding to FPR2 inhibits thermogenesis through G i cyclic adenosine monophosphate signaling pathways, an effect that is reversed in the absence of FPR2. We present three cryo–electron microscopy structures of FPR2 in complex with G i trimers bound to C16:0, C18:0, and C20:0 ceramides. The hydrophobic tails are deeply embedded in the orthosteric ligand pocket, which has a limited amount of plasticity. Modification of the ceramide binding motif in closely related receptors, such as FPR1 or FPR3, converts them from inactive to active ceramide receptors. Our findings provide a structural basis for adipocyte thermogenesis mediated by FPR2.
- Open Access
- 4 June 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-16
Sphingosine d18:1 promotes nonalcoholic steatohepatitis by inhibiting macrophage HIF-2α
Non-alcoholic steatohepatitis (NASH) is a severe type of the non-alcoholic fatty liver disease (NAFLD). NASH is a growing global health concern due to its increasing morbidity, lack of well-defined biomarkers and lack of clinically effective treatments. Using metabolomic analysis, the most significantly changed active lipid sphingosine d18:1 [So(d18:1)] is selected from NASH patients. So(d18:1) inhibits macrophage HIF-2α as a direct inhibitor and promotes the inflammatory factors secretion. Male macrophage-specific HIF-2α knockout and overexpression mice verified the protective effect of HIF-2α on NASH progression. Importantly, the HIF-2α stabilizer FG-4592 alleviates liver inflammation and fibrosis in NASH, which indicated that macrophage HIF-2α is a potential drug target for NASH treatment. Overall, this study confirms that So(d18:1) promotes NASH and clarifies that So(d18:1) inhibits the transcriptional activity of HIF-2α in liver macrophages by suppressing the interaction of HIF-2α with ARNT, suggesting that macrophage HIF-2α may be a potential target for the treatment of NASH.
- 4 June 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-16
Open AccessSphingosine d18:1 promotes nonalcoholic steatohepatitis by inhibiting macrophage HIF-2α
Non-alcoholic steatohepatitis (NASH) is a severe type of the non-alcoholic fatty liver disease (NAFLD). NASH is a growing global health concern due to its increasing morbidity, lack of well-defined biomarkers and lack of clinically effective treatments. Using metabolomic analysis, the most significantly changed active lipid sphingosine d18:1 [So(d18:1)] is selected from NASH patients. So(d18:1) inhibits macrophage HIF-2α as a direct inhibitor and promotes the inflammatory factors secretion. Male macrophage-specific HIF-2α knockout and overexpression mice verified the protective effect of HIF-2α on NASH progression. Importantly, the HIF-2α stabilizer FG-4592 alleviates liver inflammation and fibrosis in NASH, which indicated that macrophage HIF-2α is a potential drug target for NASH treatment. Overall, this study confirms that So(d18:1) promotes NASH and clarifies that So(d18:1) inhibits the transcriptional activity of HIF-2α in liver macrophages by suppressing the interaction of HIF-2α with ARNT, suggesting that macrophage HIF-2α may be a potential target for the treatment of NASH.
- Top Cited Papers
- 20 May 2024
- Published by Springer Nature in Nature Metabolism
- Vol. 6 (5) , 947-962
The microbial metabolite agmatine acts as an FXR agonist to promote polycystic ovary syndrome in female mice
Polycystic ovary syndrome (PCOS), an endocrine disorder afflicting 6–20% of women of reproductive age globally, has been linked to alterations in the gut microbiome. We previously showed that in PCOS, elevation of Bacteroides vulgatus in the gut microbiome was associated with altered bile acid metabolism. Here we show that B. vulgatus also induces a PCOS-like phenotype in female mice via an alternate mechanism independent of bile acids. We find that B. vulgatus contributes to PCOS-like symptoms through its metabolite agmatine, which is derived from arginine by arginine decarboxylase. Mechanistically, agmatine activates the farnesoid X receptor (FXR) pathway to subsequently inhibit glucagon-like peptide-1 (GLP-1) secretion by L cells, which leads to insulin resistance and ovarian dysfunction. Critically, the GLP-1 receptor agonist liraglutide and the arginine decarboxylase inhibitor difluoromethylarginine ameliorate ovarian dysfunction in a PCOS-like mouse model. These findings reveal that agmatine–FXR–GLP-1 signalling contributes to ovarian dysfunction, presenting a potential therapeutic target for PCOS management.
- 20 May 2024
- Published by Springer Nature in Nature Metabolism
- Vol. 6 (5) , 947-962
Top Cited PapersThe microbial metabolite agmatine acts as an FXR agonist to promote polycystic ovary syndrome in female mice
Polycystic ovary syndrome (PCOS), an endocrine disorder afflicting 6–20% of women of reproductive age globally, has been linked to alterations in the gut microbiome. We previously showed that in PCOS, elevation of Bacteroides vulgatus in the gut microbiome was associated with altered bile acid metabolism. Here we show that B. vulgatus also induces a PCOS-like phenotype in female mice via an alternate mechanism independent of bile acids. We find that B. vulgatus contributes to PCOS-like symptoms through its metabolite agmatine, which is derived from arginine by arginine decarboxylase. Mechanistically, agmatine activates the farnesoid X receptor (FXR) pathway to subsequently inhibit glucagon-like peptide-1 (GLP-1) secretion by L cells, which leads to insulin resistance and ovarian dysfunction. Critically, the GLP-1 receptor agonist liraglutide and the arginine decarboxylase inhibitor difluoromethylarginine ameliorate ovarian dysfunction in a PCOS-like mouse model. These findings reveal that agmatine–FXR–GLP-1 signalling contributes to ovarian dysfunction, presenting a potential therapeutic target for PCOS management.
- Open Access
- 1 September 2023
- Published by KEAI Publishing in Liver Research
- Vol. 7 (3) , 165-176
Microbial transformations of bile acids and their receptors in the regulation of metabolic dysfunction-associated steatotic liver disease
Bile acids (BAs) play important roles in the digestion of dietary fats and molecular signal transduction, and modulation of the BA composition usually affects the progression of metabolic diseases. While the liver produces primary BAs, the gut microbiota modifies these products into various forms that greatly increase their diversity and biological functions. Mechanistically, BAs can regulate their own metabolism and transport as well as other key aspects of metabolic processes via dedicated BA receptors. Disruption of BA transport and homeostasis leads to the progression of liver diseases, including metabolic dysfunction-associated steatotic liver disease (MASLD) and hepatocellular carcinoma (HCC). Here, we summarize the microbial transformations of BAs and their downstream signaling in the development of metabolic diseases and present new insights into novel therapeutic strategies targeting BA pathways that may contribute to these diseases.
- 1 September 2023
- Published by KEAI Publishing in Liver Research
- Vol. 7 (3) , 165-176
Open AccessMicrobial transformations of bile acids and their receptors in the regulation of metabolic dysfunction-associated steatotic liver disease
Bile acids (BAs) play important roles in the digestion of dietary fats and molecular signal transduction, and modulation of the BA composition usually affects the progression of metabolic diseases. While the liver produces primary BAs, the gut microbiota modifies these products into various forms that greatly increase their diversity and biological functions. Mechanistically, BAs can regulate their own metabolism and transport as well as other key aspects of metabolic processes via dedicated BA receptors. Disruption of BA transport and homeostasis leads to the progression of liver diseases, including metabolic dysfunction-associated steatotic liver disease (MASLD) and hepatocellular carcinoma (HCC). Here, we summarize the microbial transformations of BAs and their downstream signaling in the development of metabolic diseases and present new insights into novel therapeutic strategies targeting BA pathways that may contribute to these diseases.